Use of ibuprofen sustained release for treating osteoarthritic pain: findings from 15 general medical practices in Egypt

Abstract

PurposeIbuprofen sustained release (SR) has been shown to provide effective symptomatic pain relief in chronic arthritic conditions such as osteoarthritis in European and US patient populations. Few studies have been conducted in other patient populations. A 4-week prospective multicenter open-label observational study was designed to explore and describe the combined effect of ibuprofen SR and standard medical care in patients suffering from osteoarthritis in 15 general medical practices in Egypt.Patients and methodsIn total, 519 patients were prescribed ibuprofen SR 2 ×800 mg once daily for 4 weeks.ResultsIbuprofen SR combined with standard medical care significantly improved day and night pain, with 99.4% of the patients reporting improvement. The treatment reduced the symptom severity of joint tenderness/stiffness and the duration of morning stiffness, and allowed more patients to carry out normal activities. Overall compliance with the prescribed ibuprofen SR regimen was 98.6%. Ibuprofen SR was generally well tolerated with no serious adverse events reported during the study. There was no increase in blood pressure or heart rate.ConclusionThe combined treatment provided effective relief of pain in patients with osteoarthritis in a large real-life general medical practice setting in Egypt. Owing to its convenient once-daily dosing regimen, ibuprofen SR may enhance patient compliance.

Management of patients with chronic nonspecific lumbar pain

“…В Канаде анализ типичной практики назначения лекарственных средств показал, что ибупрофен относится к наиболее часто назначаемым лекарственным средствам при болях в спине [33]. В настоящее время в различных странах широко используется ибупрофен медленного высвобождения в дозе 1600 мг/сут; проведенный в Египте анализ ведения 519 пациентов с остеоартритом показал, что его ежедневный прием в течение 4 недель приводит к существенному снижению боли у большинства (99,4%) пациентов, при этом отмечается хорошая переносимость лечения, отсутствие серьезных осложнений [34].…”

Sodium Alginate Hydrogel Carrier with Calcium Carbonate as Calcium Source for Ibuprofen Release

“…Therefore, a suitable carrier needs to be developed to improve the water solubility and bioavailability of IBU. [17] SA hydrogel crosslinked with CaCl 2 has been extensively researched as a drug carrier. However, the available studies on drug delivery systems of SA hydrogel crosslinked with CaCO 3 and GDL have provided only limited investigation.…”

“…Therefore, a suitable carrier needs to be developed to improve the water solubility and bioavailability of IBU. [ 17 ]…”

Facile Synthesis of Copper‐5‐Aminoisophthalic Acid Metal Organic Framework as a Potential Drug Carrier for Ibuprofen

“…Localized and targeted delivery is attractive alternate forms of NSAID administration due to their ability to eliminate off-target effects. [7,8] Copper-5-aminoisophthalic acid (AIPA-Cu (II) MOF) has multi-coordination sites with an exciting ligand, including one amine group, one aromatic core, and two carboxylic groups. [9,10] However, minimal research has been focused on applying this kind of MOFs in drug delivery applications, which can have excellent potential performance.…”

“…Therefore, it is more advantageous to focus on improving the current available NSAID treatments, as they are generally very effective. Localized and targeted delivery is attractive alternate forms of NSAID administration due to their ability to eliminate off‐target effects [7,8] …”